An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
KORU Medical Systems Announces Novel Therapy Collaboration for Three Indications with Kira Pharmaceuticals
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Very Positive)
Tags
Rhea-AI Summary
KORU Medical Systems (NASDAQ: KRMD) has progressed its partnership with Kira Pharmaceuticals, expanding their agreement to include three new indications for Phase II studies of Kira's KP-104 program. The conditions target over 150,000 patients in the U.S. with nephrology and hematology conditions. Kira selected KORU for its proven subcutaneous therapeutic solutions, which allow treatments to be administered at home. This partnership reflects KORU's commitment to enhancing its novel therapies pipeline and improving patient care worldwide.
Positive
Expansion of partnership with Kira Pharmaceuticals into three new indications for KP-104.
Addressing significant patient population, over 150,000 in the U.S.
KORU's established track record with at-home subcutaneous infusions enhances collaboration.
Negative
None.
MAHWAH, N.J.--(BUSINESS WIRE)--
KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development of innovative and easy-to-use subcutaneous infusion solutions, today announced the progression of its agreement with Kira Pharmaceuticals, including expansion into three important additional indications.
Kira will utilize KORU Medical’s Freedom System for Phase II studies of Kira’s lead program, KP-104, an innovative, first-in-class bifunctional complement inhibitor, in three indications. These diseases, collectively affecting over 150,000 patients in the United States and estimated hundreds of thousands more globally, consist of nephrology conditions IgA Neuropathy (IgAN) and Complement 3 Glomerulopathy (C3G) and hematology condition Thrombotic Microangiopathy secondary to Systemic Lupus Erythematosus (SLE-TMA). The expanded Kira partnership reflects the previously announced collaboration with an unnamed partner for a single hematology indication.
“We selected KORU Medical based on their track record of helping patients receive high-value therapeutics subcutaneously in the comfort of their home,” said Chaomei He, Kira’s Head of Chemistry, Manufacturing, and Controls (CMC). “The Freedom System’s ease of use, global regulatory approvals, experience with tens of thousands of patients, and ability to rapidly enter the clinic gave us confidence that KORU was the right partner for our KP-104 program.”
“We are privileged to work with Kira and help them achieve their mission of helping patients living with complement-mediated disease by providing treatment at home,” said Linda Tharby, KORU Medical’s President and CEO. “The expansion of our work with Kira and progression into Phase II studies is another important milestone in our strategy to grow our novel therapies pipeline in multiple therapeutic areas.”
About KORU Medical
KORU Medical develops, manufactures, and commercializes innovative and easy-to-use subcutaneous infusion solutions that improve quality of life for patients around the world. The FREEDOM Syringe Infusion System (the “Freedom System”) currently includes the FREEDOM60® and FreedomEdge® Syringe Infusion Drivers, Precision Flow Rate Tubing™ and HIgH-Flo Subcutaneous Safety Needle Sets™. These devices are used for infusions administered in the home and alternate care settings. For more information, please visit www.korumedical.com.
What is the new partnership between KORU Medical and Kira Pharmaceuticals about?
KORU Medical has expanded its partnership with Kira Pharmaceuticals to include three new indications for Kira's KP-104 program, focusing on nephrology and hematology conditions.
How many patients could benefit from the new indications in the KORU and Kira partnership?
The new indications collectively affect over 150,000 patients in the United States.
What is the significance of KORU Medical's Freedom System in the partnership with Kira Pharmaceuticals?
Kira Pharmaceuticals chose KORU Medical's Freedom System due to its ease of use, global regulatory approvals, and experience in subcutaneous therapies that allow treatments to be given at home.
When will the Phase II studies for Kira's KP-104 program begin?
The press release does not specify the exact start date for the Phase II studies.
What are the therapeutic areas targeted by KORU Medical and Kira Pharmaceuticals in their new agreement?
The targeted therapeutic areas include IgA Neuropathy, Complement 3 Glomerulopathy, and Thrombotic Microangiopathy secondary to Systemic Lupus Erythematosus.
